good news: In recent days, the first drug delivery to Avigen has arrived in Israel, which is being considered as an effective response to the treatment of coronary disease in its early stages, reducing the time of the disease and preventing deterioration in difficult situations. The shipment arrived in Israel following the collaboration of the Israeli Embassy in Japan, the Foreign Ministry, the Ministry of Health, the CPA and Hadassah and Ichilov Medical Centers, which will also lead the Israeli trial of the drug. Last week, the first shipment arrived in Israel and the Ministry of Health approved a major multi-center trial in Israel. Which will include about 80 patients, in collaboration with Hadassah Medical Center, Ichilov, Soroka and Fertia and integration with researchers from the Hebrew University.
The Helsinki Human Clinical Trial Permits Committee convened in Hadassah on Monday to review several promising trial proposals for the treatment of corona patients and in principle approved the initiation of drug therapy. According to the plan, after full approval by the local committees and the Ministry of Health, treatment will begin, with the assessment being between days and weeks.
“The drug originally developed as a treatment for pandemic influenza is supposed to shorten the duration of the disease and the spread of the virus in inpatients of COVID19, as shown by several initial studies of this drug published in China,” explained Prof. Ran Nir Paz of Hadassah, who also flew to Japan on behalf of the Ministry of Health Diamond Princess. ” “The drug is also within the guidelines for treatment as one of the first-line drugs in Japan right now, and aims
Israeli research to test whether the drug is effective in this delineation, “he added.
Prof. Ran Nir Paz (Photo: Hadassah Hospital spokeswoman)
Dr. Estee Sage of Ichilov Hospital adds: “Within the wide variety of drugs we are trying to treat the Corona patients, some are empirically prominent, the drug Avigen, which is promising, in terms of the potential treatment for the first stages of the disease and prevention of deterioration. In doing so, it may contribute to flattening the curve and improving the ability to cope with the extent of morbidity we experience in the country. ”
The Israeli ambassador to Japan, Yaffe Ben-Ari, wanted to thank “the Japanese government and especially the Fujifilm Corporation for recognizing the importance of collaborating with Israeli medical research and Japanese appreciation of Professor Ren Nir-Paz’s high level of research proposal. We are continuing to treat another drug supply with the goal of helping Israel stop the decline in coronary disease among many more patients. ”
